Polish Pursuit: EUPATI Takes its Message to Warsaw - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
Polish Pursuit: EUPATI Takes its Message to Warsaw

Source: Applied Clinical Trials

The European Patients’ Academy on Therapeutic Innovation (EUPATI) has announced that its second workshop, “Reaching a Public Audience on Medicines Development,” will take place on April 2, 2014 at the Hotel InterContinental Warszawa, Poland.

The workshop has been designed to draw on EUPATI’s social research work involving patients and citizens across Europe, as well as to hear views from patient advocates and the public and to provide details about successful examples of information sharing. Among the attendees are likely to be representatives from stakeholder groups that have a role in the medicines development process, including patients, industry, academia, ethics committees, regulators, and medical professionals.

According to the organizers, “Breakout sessions will be used for brainstorming on the best ways to inform patients and citizens about medicines research and development. We want each workshop delegate to advise us on how EUPATI can meet the information needs of the patient community and provide information appropriately. Throughout the workshop you will have many opportunities to voice your opinions and share your thoughts. We strongly encourage open and active dialogues in Warsaw!”

EUPATI is funded by the Innovative Medicines Initiative, and aims to provide scientifically reliable, objective, comprehensive information to patients on medicines research and development. It seeks to increase the capacities and capabilities of well-informed patients and patient organizations to be effective advocates and advisors in medicines research.​


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here